I. Wertz

发表

The ubiquitin ligase COP1 is a critical negative regulator of p53

Patrick Dowd, Vishva M. Dixit, G. Frantz, 2004, Nature.

A20: from ubiquitin editing to tumour suppression

I. Wertz, S. Hymowitz, 2010, Nature Reviews Cancer.

Phospho-tuning immunity through Denisovan, modern human and mouse TNFAIP3 gene variants

Benjamin T. Porebski, G. Nolan, M. Cox, 2019, bioRxiv.

Phosphorylation and linear ubiquitin direct A20 inhibition of inflammation

Jinfeng Liu, Saritha Kusam, Jeffrey Tom, 2015, Nature.

Ubiquitylation in apoptosis: a post-translational modification at the edge of life and death

Vishva M. Dixit, V. Dixit, I. Wertz, 2011, Nature Reviews Molecular Cell Biology.

De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-κB signalling

Somasekar Seshagiri, L. Aravind, Eugene V. Koonin, 2004, Nature.

Toward understanding ubiquitin-modifying enzymes: from pharmacological targeting to proteomics.

I. Wertz, J. Lill, 2014, Trends in pharmacological sciences.

Ubiquitin Chain Editing Revealed by Polyubiquitin Linkage-Specific Antibodies

Christine Yu, Sachdev S. Sidhu, Dorothy M. French, 2008, Cell.

Antibody-mediated delivery of chimeric protein degraders which target estrogen receptor alpha (ERα).

C. Li, R. Rowntree, BinQing Wei, 2019, Bioorganic & medicinal chemistry letters.

COP1 is a tumour suppressor that causes degradation of ETS transcription factors

K. Leong, V. Dixit, Jinfeng Liu, 2011, Nature.

HectD1 E3 Ligase Modifies Adenomatous Polyposis Coli (APC) with Polyubiquitin to Promote the APC-Axin Interaction

Anjali A. Sarkar, I. Wertz, S. Shriver, 2012, The Journal of Biological Chemistry.

Activity‐based probes for the ubiquitin conjugation–deconjugation machinery: new chemistries, new tools, and new insights

M. Bogyo, I. Wertz, D. Hewings, 2017, The FEBS journal.

Bcl10 activates the NF-kappaB pathway through ubiquitination of NEMO.

Honglin Zhou, S. Seshagiri, M. Ultsch, 2004, Nature.

Human De-Etiolated-1 Regulates c-Jun by Assembling a CUL4A Ubiquitin Ligase

R. Deshaies, Zemin Zhang, V. Dixit, 2004, Science.

Yersinia virulence factor YopJ acts as a deubiquitinase to inhibit NF-κB activation

Honglin Zhou, V. Dixit, I. Wertz, 2005, The Journal of experimental medicine.

PIKES Analysis Reveals Response to Degraders and Key Regulatory Mechanisms of the CRL4 Network.

Kurt M. Reichermeier, Justin M. Reitsma, Michael J. Sweredoski, 2020, Molecular cell.

Reactive-site-centric chemoproteomics identifies a distinct class of deubiquitinase enzymes

M. Bogyo, W. Forrest, N. Popovych, 2018, Nature Communications.

Activity‐based probes for the multicatalytic proteasome

M. Bogyo, I. Wertz, D. Hewings, 2017, The FEBS journal.

Molecular glue CELMoD compounds are allosteric regulators of cereblon conformation

P. Griffin, G. Lander, I. Wertz, 2022, bioRxiv.

Molecular glue CELMoD compounds are regulators of cereblon conformation

P. Griffin, G. Lander, I. Wertz, 2022, Science.

Molecular Understanding of USP7 Substrate Recognition and C-Terminal Activation.

J. Ernst, I. Wertz, P. Di Lello, 2016, Structure.

It takes two to tango: a new couple in the family of ubiquitin-editing complexes

I. Wertz, 2011, Nature Immunology.

Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)

C. Tse, D. Anderson, Daniel J. Anderson, 2015, Cell Death and Disease.

Diverse molecular provocation of programmed cell death.

I. Wertz, M. Hanley, 1996, Trends in biochemical sciences.

Bcl10 activates the NF-κB pathway through ubiquitination of NEMO

Honglin Zhou, S. Seshagiri, M. Ultsch, 2004, Nature.

Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility

Mamie Yu, A. Daemen, R. Houtman, 2019, Cell.

Denisovan, modern human and mouse TNFAIP3 alleles tune A20 phosphorylation and immunity

Benjamin T. Porebski, G. Nolan, M. Cox, 2019, Nature Immunology.

Loss-of-function mutations in TNFAIP3 leading to A20 haploinsufficiency cause an early onset autoinflammatory syndrome

J. Mullikin, Yuan Zhang, D. Kastner, 2015, Nature Genetics.

DUBs, the regulation of cell identity and disease.

I. Wertz, J. Heideker, 2015, The Biochemical journal.

Ubiquitin binding to A20 ZnF4 is required for modulation of NF-κB signaling.

V. Dixit, I. Wertz, D. Arnott, 2010, Molecular cell.

Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7

Adam R. Johnson, S. Seshagiri, J. Kaminker, 2011, Nature.

A20--a bipartite ubiquitin editing enzyme with immunoregulatory potential.

V. Dixit, I. Wertz, 2014, Advances in experimental medicine and biology.

Identifying transcriptional programs underlying cancer drug response with TraCe-seq

Z. Modrušan, Matthew T. Chang, S. Malek, 2021, Nature Biotechnology.

Structurally-defined deubiquitinase inhibitors provide opportunities to investigate disease mechanisms.

I. Wertz, J. Murray, 2019, Drug discovery today. Technologies.

USP7 small-molecule inhibitors interfere with ubiquitin binding

Florian Gnad, Scott E. Martin, Michelle R. Arkin, 2017, Nature.

Characterization of Calcium Release-activated Apoptosis of LNCaP Prostate Cancer Cells*

V. Dixit, I. Wertz, 2000, The Journal of Biological Chemistry.

Targeted protein degradation: from small molecules to complex organelles—a Keystone Symposia report

J. Frydman, M. Słabicki, C. Bertozzi, 2022, Annals of the New York Academy of Sciences.

Regulation of death receptor signaling by the ubiquitin system

V. Dixit, I. Wertz, IE Wertz, 2010, Cell Death and Differentiation.

Ubiquitin-mediated regulation of TNFR1 signaling.

V. Dixit, I. Wertz, 2008, Cytokine & growth factor reviews.

The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer

K. Walter, Andiliy G. Lai, J. Giltnane, 2016, eLife.

Signaling to NF-kappaB: regulation by ubiquitination.

V. Dixit, I. Wertz, 2010, Cold Spring Harbor perspectives in biology.

Ubiquitination in the regulation of inflammatory cell death and cancer

I. Wertz, Si-Han Chen, D. Vučić, 2021, Cell Death & Differentiation.

GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast Cancer.

Siew K. Yeap, N. C. Ray, Jun Liang, 2021, Journal of medicinal chemistry.

Erratum: Phosphorylation and linear ubiquitin direct A20 inhibition of inflammation

J. DeVoss, D. Seshasayee, W. Sandoval, 2016, Nature.

DUBs, the regulation of cell identity and disease.

I. Wertz, J. Heideker, 2015, The Biochemical journal.

Targeting MCL‐1 and BCL‐2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non‐Hodgkin lymphoma: Results from preclinical models and a Phase Ib study

Dhara N. Amin, N. Johnson, M. Krem, 2023, American journal of hematology.

Signaling to NFk B : Regulation by Ubiquitination

V. Dixit, I. Wertz, 2010 .

TNFR1-activated NF-κB signal transduction: regulation by the ubiquitin/proteasome system.

I. Wertz, 2014, Current opinion in chemical biology.

Conformational stabilization of ubiquitin yields potent and selective inhibitors of USP7.

Jacob E. Corn, W. Sandoval, J. Corn, 2013, Nature chemical biology.

Antibody toolkit reveals N-terminally ubiquitinated substrates of UBE2W

A. Peterson, I. Wertz, J. Sudhamsu, 2021, Nature Communications.

Reactive-site-centric chemoproteomics identifies a distinct class of deubiquitinase enzymes

M. Bogyo, W. Forrest, N. Popovych, 2018, Nature Communications.

Rapid, semi-automated protein terminal characterization using ISDetect

W. Sandoval, I. Wertz, C. Bakalarski, 2016, Nature Biotechnology.

From Discovery to Bedside: Targeting the Ubiquitin System.

I. Wertz, Xiaojing Wang, 2019, Cell chemical biology.

Tumor Necrosis Factor Alpha Induced Protein 3 (TNFAIP3)

I. Wertz, 2013 .

Targeted mass spectrometric strategy for global mapping of ubiquitination on proteins.

V. Dixit, I. Wertz, D. Arnott, 2007, Rapid communications in mass spectrometry : RCM.

Identifying transcriptional programs underlying cancer drug response with TraCe-seq

Z. Modrušan, Matthew T. Chang, S. Malek, 2021, Nature Biotechnology.

Constitutive protein degradation induces acute cell death via proteolysis products

L. Kenner, I. Wertz, W. Fairbrother, 2023, bioRxiv.

Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7

Adam R. Johnson, S. Seshagiri, J. Kaminker, 2011, Nature.

Correlation of genetic and immunodetection of TP53 mutations in malignant and benign prostate tissues.

A. Deitch, P. Gumerlock, I. Wertz, 1996, Human pathology.

Conjugation of Indoles to Antibodies through a Novel Self-Immolating Linker.

R. Rowntree, B. Vollmar, I. Wertz, 2018, Chemistry.

Primary Amine Tethered Small Molecules Promote the Degradation of X-Linked Inhibitor of Apoptosis Protein.

Melinda M. Mulvihill, I. Wertz, W. Fairbrother, 2021, Journal of the American Chemical Society.

Targeted degradation via direct 26S proteasome recruitment

C. Ciferri, N. Popovych, I. Wertz, 2022, Nature Chemical Biology.

Discovery of Small-Molecule Inhibitors of Ubiquitin Specific Protease 7 (USP7) Using Integrated NMR and in Silico Techniques.

I. Wertz, P. Di Lello, L. Kategaya, 2017, Journal of medicinal chemistry.

Abstract P5-04-07: GDC-9545: A novel ER antagonist and clinical candidate that combines desirable mechanistic and pre-clinical DMPK attributes

A. Daemen, J. Giltnane, L. Friedman, 2019, Poster Session Abstracts.

Length Matters: MINDY Is a New Deubiquitinase Family that Preferentially Cleaves Long Polyubiquitin Chains.

I. Wertz, T. Maurer, 2016, Molecules and Cells.

Abstract CT133: Targeting BCL-2 and MCL-1 overcomes treatment resistance in relapsed and refractory non-Hodgkin lymphoma: Pre-clinical rationale and results from an open-label phase 1b study

Dhara N. Amin, C. Flowers, M. Krem, 2020 .

Targeting the Hippo pathway in cancers via ubiquitination dependent TEAD degradation

Thijs J. Hagenbeek, Z. Modrušan, I. Wertz, 2023, bioRxiv.

Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility

Mamie Yu, A. Daemen, R. Houtman, 2019, Cell.

Yersinia virulence factor YopJ acts as a deubiquitinase to inhibit NF-κB activation

Honglin Zhou, V. Dixit, I. Wertz, 2005, The Journal of experimental medicine.